Personalized mRNA vaccine for ovarian cancer after surgery
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tests a personalized mRNA vaccine (NeoOVIV) for ovarian cancer patients who have already had surgery. The vaccine is designed to train your immune system to attack cancer cells that remain after surgery, based on unique markers in your tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 75 years old.
- You have epithelial ovarian cancer at stage II or stage III, and have had surgery to remove the tumor.
- Doctors confirmed that no visible cancer was left after surgery, based on a scan.
- You are healthy enough to be up and about (able to do light housework or office work).
- Your kidney, liver, and blood counts are within certain safe limits.
- You have not received a cancer vaccine or certain immune therapies before this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized vaccine (NeoOVSV) made from your tumor’s unique markers (neoantigens). It’s for women with Stage II or III epithelial ovarian cancer who had successful surgery to remove all visible cancer. The goal is to see if the vaccine is safe and helps your immune system fight any remaining cancer cells.
This trial tests a personalized cancer vaccine made from your own tumor cells. It is for women with advanced ovarian, fallopian tube, or primary peritoneal cancer that has returned after at least one round of platinum chemotherapy.
This trial tests a personalized vaccine for people with epithelial ovarian cancer who still have a small amount of cancer DNA in their blood after surgery. The goal is to see if the vaccine can help stop the cancer from coming back.
This trial tests a personalized vaccine made from your own immune cells and tumor mutations. It's for people with HRD-negative ovarian cancer who still have signs of cancer after standard treatment.
This study tests a personalized cancer therapy designed just for you and your tumor. It is for people with newly diagnosed advanced ovarian cancer who can wait a short time before starting treatment and plan to have surgery after 2 cycles of chemotherapy.
This trial tests a personalized mRNA vaccine made from your tumor's unique mutations. It's given after surgery to help your immune system fight any remaining cancer cells and prevent the cancer from coming back.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.